Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2006

View Archived Issues

Studies assess pharmacodynamics, mechanism of action of ceftobiprole

Studies assess cancer prevention with selenium compounds

Schering-Plough selects compound for metabolic disease from collaboration

Reata licenses tricyclic bis-enones antiinflammatory compounds

Cytokinetics studies SB-743921 for NHL

PhG-alpha1 delays establishment and growth of colorectal cancer tumors in mice

Positive results for CRx-170 in proof-of-concept asthma study

Schering AG Boards recommend acceptance of Bayer offer

Isis licenses HIV inhibitor ISIS-5320 to ImQuest

Technosphere Insulin System improves HbA1c in phase II study

Schering-Plough updates status of phase II study of SCH-503034

Chiron shareholders approve acquisition by Novartis

Nonapprovable letter for Hexvix NDA

New compound class from Trubion Pharmaceuticals for B-cell chronic lymphocytic leukemias

PRX-08066 reduces systolic pulmonary blood pressure in study

Antitumor efficacy of new CD40 agonist antibody

Vesicare approved as first drug for overactive bladder in Japan

Funguard approved for use in children in Japan

Chugai seeks Japanese approval for Avastin in colorectal cancer

Japanese approval for Cetrotide for premature ovulation

New treatments for cancer covered in recent patents

Zometa receives new approval in Japan

AmBisome receives Japanese approval

Feron approved in Japan for compensatory cirrhosis C

Japanese approval for Nu-Lotan in diabetic nephropathy

HIV integrase inhibitors claimed in recent Pfizer patent

Novel cathepsin K inhibitor as a potential antiresorptive agent to treat osteoporosis

Synthesis and in vitro evaluation of new potent GAR Tfase inhibitor

Multinational phase III study shows positive results for panitumumab in metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...